US2007178134A1PendingUtilityA1
Pyridines and uses thereof
Est. expiryApr 4, 2023(expired)· nominal 20-yr term from priority
A61L 31/10A61L 27/34C07D 213/74C07D 213/75
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
Claims
exact text as granted — not AI-modified1 . A compound or physiologically acceptable salt thereof, wherein the compound has the formula:
wherein:
X, Y and Z are N, CH or CR where R is alkyl, alkoxy, Cl, Br, NH 2 , NHR′ or NR′R″ where R′ and R″ independently are alkyl;
Q is NR, RN—(CH 2 ) n , (CH 2 ) n —NR, O, O—(CH 2 ) n , (CH 2 ) n —O, S, S—(CH 2 ) n , or (CH 2 ) n —S, where n is 1-10 and R is H or alkyl;
R 1 is H, OH, alkyl, alkoxy, Cl, F, Br, CR 3 where R 3 is Cl 3 , F 3 or Br 3 , NH 2 , NHR or NRR′ where R and R′ independently are alkyl;
R 2 is H, OH, alkyl, alkoxy, Cl, F, Br or CR 3 where R 3 is Cl 3 , F 3 or Br 3 ;
R 3 is H, alkyl, alkoxy, Cl, CCl 3 , NH 2 , NHR or NRR′ where R and R′ independently are alkyl or acyl;
R 4 , R 5 , and R are independently H, OH, alkyl, alkenyl, alkynyl, alkoxy, (CH 2 ) n —OR where R is H or alkyl and n is 1-10, Cl, F, Br, CR 3 where R 3 is Cl 3 , F 3 or Br 3 heterocycle, N + (═O)O − , C≡N, N 3 , SH, SR or S(═O) 2 R where R is alkyl, NH 2 , NHR or NRR′ where R and R′ independently are alkyl, or R 4 and R 5 or R 5 and R 6 are taken together with the benzene ring to form a heterocycle;
and with the proviso that one of X, Y and Z is N.
2 . The compound or salt thereof of claim 1 wherein X or Y of the compound or salt thereof is N.
3 . The compound or salt thereof of claim 1 wherein Q of the compound or salt thereof is NH.
4 . The compound or salt thereof of claim 1 wherein R 4 or R 5 of the compound or salt thereof is acyl.
5 . The compound or salt thereof of claim 1 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
6 . The compound or salt thereof of claim 1 wherein R 2 of the compound or salt thereof is Cl or Br.
7 . The compound or salt thereof of claim 1 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
8 . The compound or salt thereof of claim 1 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
9 . The compound or salt thereof of claim 1 wherein the compound is any one of compounds 1-14 of Table 1, or physiologically acceptable salts thereof.
10 . A pharmaceutical composition comprising a compound or salt thereof according to claim 1 in combination with a pharmaceutically acceptable carrier or diluent.
11 . The pharmaceutical composition of claim 10 wherein X or Y of the compound or salt thereof is N.
12 . The pharmaceutical composition of claim 10 wherein Q of the compound or salt thereof is NH.
13 . The pharmaceutical composition of claim 10 wherein R 4 or R 5 of the compound or salt thereof is acyl.
14 . The pharmaceutical composition of claim 10 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
15 . The pharmaceutical composition of claim 10 wherein R 2 of the compound or salt thereof is Cl or Br.
16 . The pharmaceutical composition of claim 10 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
17 . The pharmaceutical composition of claim 10 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
18 . The pharmaceutical composition of claim 10 wherein the compound is any one of compounds 1-14 of Table 1, or physiologically acceptable salts thereof.
19 . A method for reducing the activity of lysophosphatidic acid acyltransferase β (LPAAT-β) comprising contacting LPAAT-β with a compound or salt thereof according to claim 1 or a composition according to claim 10 in an amount effective to reduce LPAAT-β activity.
20 . The method of claim 19 wherein the LPAAT-β resides in an animal.
21 . The method of claim 20 wherein the animal is a mammal.
22 . The method of claim 19 wherein X or Y of the compound or salt thereof is N.
23 . The method of claim 19 wherein Q of the compound or salt thereof is NH.
24 . The method of claim 19 wherein R 4 or R 5 of the compound or salt thereof is acyl.
25 . The method of claim 19 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
26 . The method of claim 19 wherein R 2 of the compound or salt thereof is Cl or Br.
27 . The method of claim 19 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
28 . The method of claim 19 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
29 . The method of claim 19 wherein the compound is any one of compounds 1-14 of Table 1, or physiologically acceptable salts thereof.
30 . A method for inhibiting the proliferation of a cell in which the activity of lysophosphatidic acid acyltransferase β (LPAAT-β) is required for the proliferation of the cell comprising contacting the cell with a compound or salt thereof according to claim 1 or a composition according to claim 10 in an amount effective to inhibit the proliferation of the cell.
31 . The method of claim 30 wherein the cell resides in an animal.
32 . The method of claim 31 wherein the animal is a mammal.
33 . The method of claim 30 wherein X or Y of the compound or salt thereof is N.
34 . The method of claim 30 wherein Q of the compound or salt thereof is NH.
35 . The method of claim 30 wherein R 4 or R 5 of the compound or salt thereof is acyl.
36 . The method of claim 30 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
37 . The method of claim 30 wherein R 2 of the compound or salt thereof is Cl or Br.
38 . The method of claim 30 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
39 . The method of claim 30 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
40 . The method of claim 30 wherein the compound is any one of compounds 1-14 of Table I, or physiologically acceptable salts thereof.
41 . A method for treating a cancer in which lysophosphatidic acid acyltransferase β (LPAAT-β) activity is associated comprising administering to an animal in need, a compound or salt thereof according to claim 1 or a composition according to claim 10 in an amount effective to treat the cancer.
42 . The method of claim 41 wherein the animal is a mammal.
43 . The method of claim 41 wherein X or Y of the compound or salt thereof is N.
44 . The method of claim 41 wherein Q of the compound or salt thereof is NH.
45 . The method of claim 41 wherein R 4 or R 5 of the compound or salt thereof is acyl.
46 . The method of claim 41 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
47 . The method of claim 41 wherein R 2 of the compound or salt thereof is Cl or Br.
48 . The method of claim 41 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
49 . The method of claim 41 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
50 . The method of claim 41 wherein the compound is any one of compounds 1-14 of Table 1, or physiologically acceptable salts thereof.
51 . A coated medical device for inhibiting the proliferation of a cell in which the activity of lysophosphatidic acid acyltransferase β (LPAAT-β) is required for the proliferation of the cell comprising a medical device coated with a compound or salt thereof according to claim 1 or a composition according to claim 10 .
52 . The device of claim 51 wherein X or Y of the compound or salt thereof is N.
53 . The device of claim 51 wherein Q of the compound or salt thereof is NH.
54 . The device of claim 51 wherein R 4 or R 5 of the compound or salt thereof is acyl.
55 . The device of claim 51 wherein R 1 of the compound or salt thereof is alkyl, alkoxy or Cl.
56 . The device of claim 51 wherein R 2 of the compound or salt thereof is Cl or Br.
57 . The device of claim 51 wherein R 3 of the compound or salt thereof is alkyl or NH 2 .
58 . The device of claim 51 wherein R 4 or R 5 of the compound or salt thereof is alkyl, Cl, Br, CF 3 , CH 2 —OH, (CH 2 ) 2 —OH, N + (═O)O − , C≡N, or C(═O)R wherein R is alkyl or alkoxy, or R 4 and R 5 are taken together with the benzene ring to form indazole.
59 . The device of claim 51 wherein the compound is any one of compounds 1-14 of Table 1, or physiologically acceptable salts thereof.Join the waitlist — get patent alerts
Track US2007178134A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.